Screener
Organon OGN Fosamax — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Organon’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 8:46 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029532
| ($ in millions) | Three Months Ended March 31, 2025 / U.S. | 2025 / Int’l | Total | U.S. | Int’l | Total |
|---|---|---|---|---|---|---|
| Other Respiratory (1) | 11 | 1 | 12 | 10 | 3 | 13 |
| Non-Opioid Pain, Bone and Dermatology | ||||||
| Arcoxia | — | 59 | 59 | — | 62 | 62 |
| Fosamax | — | 29 | 29 | 1 | 32 | 33 |
| Diprospan | — | 35 | 35 | — | 30 | 30 |
| Vtama | 23 | 2 | 25 | 20 | 4 | 24 |
| Other Non-Opioid Pain, Bone and Dermatology (1) | 3 | 65 | 68 | 4 | 65 | 68 |
| Other |
Item 1. Financial Statements (unaudited)
FAQ
- What is Organon's fosamax — revenue?
- Organon (OGN) reported fosamax — revenue of $29M in Q1 2026.
- How has Organon's fosamax — revenue changed year-over-year?
- Organon's fosamax — revenue decreased by 12.1% year-over-year, from $33M to $29M.
- What is the long-term trend for Organon's fosamax — revenue?
- Over 4 years (2021 to 2025), Organon's fosamax — revenue has grown at a -5.1% compound annual growth rate (CAGR), from $176M to $143M.
- What does fosamax — revenue mean?
- Represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeutic brand within the company's portfolio. This metric tracks the commercial performance and market demand for the product over a defined fiscal period. It serves as a key indicator of the product's contribution to the company's overall top-line growth and market relevance.
Ask your AI about Organon's fosamax — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude